RIGI and cancer: In contrast to RIG-I, PTIR1 could bind to the C-terminus of UCHL5 and activate its ubiquitinating function, leading to the inhibition of immunoproteasome activity and the restriction of neoantigen processing and presentation, thereby impeding T cell recognition and immune attack on cancer (51).